Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: an observational population-based study
Current epidemiological data suggest that patients with diabetes, in particular type 2 diabetes, have an increased risk of developing different types of neoplasms. [1,2] In particular, higher incidence has been observed for breast [2 –4], endometrial [2,5,6], pancreatic, colorectal [2,4,7] and liver cancer. [2,7] Metformin has become one of the most widely used drugs in the treatment of type 2 diabetes mellitus (T2DM) and is the first-line therapy for patients with T2DM according to the American Diabetes Association/European A ssociation for Study of Diabetes guidelines.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Massimo Vicentini, Paola Ballotari, Paolo Giorgi Rossi, Francesco Venturelli, Claudio Sacchettini, Marina Greci, Lucia Mangone, Annamaria Pezzarossi, Valeria Manicardi Tags: Invited review Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Endometrial Cancer | Epidemiology | Fortamet | Liver | Metformin | Pancreas | Pancreatic Cancer | Study | Urology & Nephrology